InvestSMART

Aumake Limited (ASX:AUK)

ALERT: Price-sensitive ASX Announcement for AUK
Current share price for AUK : $0.003 0.001 (20%)+
Announcement
Release
18 Dec 2025 9:19AM
Price at Release
$0.003
Full Release
download
Summary
Aumake Limited has announced its strategic entry into the high-growth over-the-counter (OTC) medicine market in China by obtaining a Hong Kong pharmaceutical wholesale license. This license allows the company to establish up to five compliant online OTC stores using major e-commerce platforms to serve Chinese consumers. Aumake plans to capitalize on China's evolving healthcare system, which is shifting towards self-medication and outpatient medication, creating significant demand for cross-border OTC products. The market is estimated at over USD 230 billion annually with online sales rapidly increasing. Aumake's strategy leverages its established cross-border e-commerce capabilities, direct sourcing agreements with international OTC brands, and extensive experience with platforms like Tmall Global and JD Global. The company aims to further expand by considering an additional license to facilitate the creation of more online stores. This expansion aligns with Aumake's goal of offering a broader range of high-margin products and strengthening its market position in China.
Key Points
  • Aumake enters China's OTC medicine market with a new Hong Kong pharmaceutical wholesale license.
  • The license allows up to five compliant online OTC stores on major e-commerce platforms.
  • China's healthcare shift towards self-medication and outpatient care is driving OTC demand.
  • The Chinese OTC market exceeds USD 230 billion annually, with online sales growing rapidly.
  • Aumake's strategy utilizes its operational capabilities and established e-commerce channels.
  • The company plans to expand with an optional second wholesale license for five more stores.
  • This expansion supports Aumake's goal of offering high-margin cross-border OTC products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.